Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Recurrence 1

Interventions

Cyclophosphamide 17fludarabine 13Dexamethasone 12Cisplatin 12Rituximab 10Gemcitabine 9Paclitaxel 8Bendamustine Hydrochloride 8Lenalidomide 7Decitabine 7Cytarabine 7Carboplatin 7fludarabine phosphate 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Etoposide 6Bortezomib 6Radiotherapy 5Injections 5Azacitidine 5camrelizumab 4apatinib 4Valproic Acid 4Thalidomide 4Procarbazine 4Oxaliplatin 4Drug Therapy 4Bevacizumab 4Antilymphocyte Serum 4venetoclax 3pomalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Recurrence × BEBT-908 × Clear all
NCT06074107 2023-10-11

Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects

BeBetter Med Inc

Phase 2 Unknown
128 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡